

# EMMA VIENNA – Program

**Thursday, January 26, 2023**

## **EDUCATIONAL DINNER BUFFET**

**Welcome**

**Heinz Ludwig and Jesús San Miguel**

**19.00 Buffet opening**

**19.30-20.00 Management of patients with solitary plasmacytoma, extramedullary myeloma and plasma cell leukemia**

**Kwee Yong**

**Friday, January 27, 2023**

**8.30-8.40 Opening**

**Heinz Ludwig and Jesús F. San-Miguel**

## **MYELOMA BIOLOGY AND RISK STRATIFICATION**

**Moderator: Heinz Ludwig**

**8.40-9.00 Molecular pathogenesis of MM**

**Niccolò Bolli**

**9.00-9.20 The role of the immune environment in evolution and course of myeloma**

**Charlotte Pawlyn**

**9.20-9.40 Genetic risk classification of multiple myeloma**

**Jill Corre**

**9.40-10.10 Discussion around important questions**

- Do genomic patterns predict progression of SMM
- Should MGUS/SMM be classified according genomic patterns

- What can be done to modify the immune environment
- Has the time come for revision of risk factors
- Are epigenetic compounds underused

## **10.10-10.30 BREAK**

### **NOVEL DEVELOPMENTS IN DISEASE AND RESPONSE ASSESSMENT**

Moderator: Jesús San Miguel

#### **10.30-10.50 MRD based treatment decisions - ready for clinical practice?**

Bruno Paiva

#### **10.50-11.10 Standard and novel imaging approaches in multiple myeloma**

Elena Zamagni

#### **11.10-11.30 Circulating plasma cells and mass spectrometry for diagnosis, disease evaluation, and prognostication**

Noemi Puig

#### **11.30 -12.00 Discussion around important questions**

- Requirements of regulatory agencies for approving MRD
- Circulating plasma cells for disease and response assessment
- Optimizing imaging technologies – MRI and PET/CT
- Impact of higher M-protein detection sensitivity (MGUS and MRD)
- MRD assessment and MGUS-like MM

### **WORKSHOPS**

#### **12.00-12.45 Prevention and treatment of bone disease**

Evangelos Terpos

**12.00-12.45 Management of patients with high-risk disease**

Francesca Gay

**12.00-12.45 MGRS and management of cast nephropathy induced acute renal failure**

Graham Jackson

**12.45- 13.45 LUNCH**

**MANAGEMENT OF PATIENTS WITH SMOLDERING AND TRANSPLANT ELIGIBLE DISEASE**

Moderator: Heinz Ludwig

**13.45-14.05 Risk classification of MGUS and SMM**

Heinz Ludwig

**14.05-14.25 Is autologous transplantation still the optimal approach in young patients?**

Philippe Moreau

**14.25-14.45 Expanding options for maintenance treatment**

Michele Cavo

**14.45-15.15 Discussion around important questions**

- Can prediction of early progression in SMM be further improved?
- Upfront ASCT yields longer PFS but similar OS compared to delayed or no ASCT. Does this principle apply to SMM as well?
- What is the optimal number of induction and consolidation cycles?
- MRD guide therapy ready for prime time?
- Maintenance therapy tomorrow?

## **15.15-15.35 BREAK**

### **MANAGEMENT OF TRANSPLANT INELIGIBLE PATIENTS**

Moderator: Jesús San Miguel

#### **15.35-15.55 Classification of fitness and comorbidities of patients not eligible for ASCT**

Alessandra Larocca

#### **15.55-16.15 How do I select treatment for TNE patients? Pros and Cons for continued treatment**

Thierry Facon

#### **16.15-16.45 Discussion of important questions**

- Treatment of very elderly patients
- Myeloma related versus other comorbidities
- Initiation of therapy at biochemical progression
- Treatment duration
- Impact of individual risk on treatment selection

## **16.45-17.30 WORKSHOPS (repeated)**

### **KEYNOTE LECTURE**

#### **17.30-18.00 Multiple myeloma research and treatment on the move. A look into the future**

Jesús San-Miguel

**Saturday, January 28, 2023**

**THE BEST APPROACH TO PATIENTS WITH RELAPSED/REFRACTORY DISEASE**

Moderator: Heinz Ludwig

**8.30-8.50 How I select therapy after relapse to one or two prior treatment lines**

Marivi Mateos

**8.50-9.10 Treatment strategies in patients after  $\geq 3$  relapses**

Mohammad Mothy

**9.10-9.30 Recently approved drugs and new CELMoDs**

Paula Rodriguez-Otero

**9.30-10.00 Discussion of important questions**

- Limitations of the definition of refractoriness
- Management of early relapse
- Lenalidomide refractory patients
- CD38 retreatment
- Optimizing therapy in high-risk RRMM patients

**10.00-10.20 BREAK**

**HOT TOPICS IN MYELOMA**

Moderator: Jesús San Miguel

**10.20- 10.40 BiTEs and monoclonal antibodies**

Niels van de Donk

### **10.40 -11.00 CAR-T cells and other cellular therapies**

Hermann Einsele

#### **11.00-11.30 Discussion of important questions**

- Resistance mechanisms for CD38 antibodies
- Is there an optimal target for BiTEs and CAR-T cells?
- Pros and cons for BiTEs or CAR-T cells
- Impact of CAR-T cell persistence on outcome
- Prevention of toxicities of BiTEs and CAR-T cells

## **AMYLOIDOSIS AND WADENSTRÖM'S DISEASE**

Moderator: Heinz Ludwig

### **11.30-11.50 New developments in the management of Amyloidosis**

Giampaolo Merlini

### **11.50-12.10 New developments in the management of Waldenström's disease**

Melitios A. Dimopoulos

#### **12.10-12.40 Discussion of important questions**

- Is cure a realistic goal in amyloidosis?
- Cellular therapies in amyloidosis
- Treatment of patients failing to first-line treatment with PTK inhibitors and CD20+ base therapies
- Should anti-BCMA treatments be explored in Waldenström's disease as 2/3 express BCMA on their tumor clones?

### **12.40-12.50 Closure of the meeting**

Heinz Ludwig and Jesús San Miguel